Clinical trials: Arthritis, Unspecified
Systemic Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
- Trial name
- NCT00144612
- Testing
- MRA(Tocilizumab)
- Volunteers
- 60 people
- Sponsor
- Chugai Pharmaceutical
Inflammation, Rheumatoid Arthritis
Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this trial is to evaluate the change in disease activity following 12 weekly s.c. (under the skin) doses of NNC109-0012 compared to placebo in subjects with active Rheumatoid…
- Trial name
- NCT01282255
- Testing
- NNC109-0012
- Where
- 29 sites in Czechia, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Knee Osteoarthritis
Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II
Study objectives: Part 1 TDU11685 To assess in patients with knee Osteoarthritis (OA), the safety, tolerability and pharmacokinetics (PK) of single intra-articular doses of SAR113945.
- Trial name
- NCT01598415
- Testing
- SAR113945
- Where
- 2 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Sanofi
Osteoarthritis, Knee, Osteoarthritis, Hip
Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or…
- Trial name
- NCT02447276
- Testing
- REGN475
- Where
- 72 sites in United States
- Volunteers
- 421 people
- Sponsor
- Regeneron Pharmaceuticals
Degenerative Joint Disease, Osteoarthritis, Hip
Safety and Effectiveness of the HIT Reverse HRS
The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement.
- Conditions
- Degenerative Joint Disease, Osteoarthritis, Hip, Avascular Necrosis of Hip, Traumatic Arthropathy-Hip
- Trial name
- NCT05357378
- Testing
- Hip Innovation Technology Reverse Hip Replacement System, Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.
- Where
- 6 sites in United States
- Volunteers
- 288 people
- Sponsor
- Hip Innovation Technology
Arthritis, Rheumatoid
SB-681323 In Subjects With Rheumatoid Arthritis
The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.
- Trial name
- NCT00320450
- Testing
- SB-681323
- Where
- 41 sites in Denmark, Germany and 7 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to estimate the effect of anakinra, 100 mg once daily (QD), on the development of an anti-tetanus antibody response in subjects with RA after vaccination with a tetanus and diphtheria toxoids…
- Trial name
- NCT00111410
- Testing
- Anakinra (r-metHuIL-1ra)
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Knee Osteoarthritis, Intra-Articular Injection
Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one®
The objective of this trial is to assess the clinical pertinence of an innovative analytical tool (SYNODIAG) to analyze the Synovial Fluid (SF) composition and guide the patient treatment in a Proof of Concept (PoC) study using…
- Trial name
- RESYF (NCT04321668)
- Testing
- Synvisc-One
- Where
- 3 sites in Belgium
- Volunteers
- 13 people
- Sponsor
- Pulsalys
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Degenerative Arthritis
Vanguard Knee Anterior Stabilized Versus Posterior Stabilized Bearing Study
The purpose of this study is to compare the performance of two FDA-cleared tibial bearings (replacement for cartilage in the knee) by collecting data on patients through 3 years of follow-up.
- Trial name
- VGASPS (NCT01308515)
- Testing
- Vanguard Knee System with AS Bearing, Vanguard Knee System with PS Bearing
- Sponsor
- Zimmer Biomet
Osteoarthritis, Arthritis
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo.
- Conditions
- Osteoarthritis, Arthritis, Pain
- Trial name
- NCT01089725
- Testing
- Tanezumab SC, Tanezumab IV
- Where
- 91 sites in United States
- Volunteers
- 385 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to…
- Trial name
- NCT05133297
- Testing
- TLL-018, Tofacitinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Osteoarthritis, Post-traumatic Arthritis
ATTUNE Single-Use Instrumentation vs. ATTUNE Reusable Instrumentation in Primary Total Knee Arthroplasty
This post-marketing investigation will evaluate the mechanical axis alignment achieved with the ATTUNE Single-Use Instrumentation (SUI) as compared to the mechanical axis alignment achieved with the ATTUNE Reusable…
- Trial name
- SOLO (NCT02574312)
- Testing
- ATTUNE TKA with ATTUNE RUI, ATTUNE TKA with ATTUNE SUI
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 88 people
- Sponsor
- DePuy Orthopaedics
Rheumatoid Arthritis (RA
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
- Trial name
- NCT06994143
- Testing
- CLN-978
- Where
- 4 sites in Germany, Italy
- Volunteers
- 37 people
- Sponsor
- Cullinan Therapeutics Inc.
Ankylosing Spondylitis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
- Trial name
- NCT01220518
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 1 (NCT02760368)
- Testing
- Olokizumab
- Where
- 40 sites in Belarus, Bulgaria and 1 more
- Volunteers
- 428 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy
This observational multicenter study will evaluate the management of disease and safety in clinical practice in patients with moderate to severe rheumatoid arthritis receiving any biological therapies in monotherapy.
- Trial name
- NCT01664117
- Where
- 41 sites in Spain
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems
MicroPort Orthopedics (MPO) is conducting this PMCF study to evaluate the safety and efficacy of its THA and resurfacing components marketed in the EU.
- Trial name
- NCT02314702
- Testing
- PROFEMUR® L Revision Femoral Stem
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- MicroPort Orthopedics Inc.
Osteoarthritis of the Knee
Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis
The purpose of this study is to evaluate the safety and efficacy of Hydros-TA Joint Therapy for relief of pain due to OA of the knee.
- Trial name
- NCT02022930
- Testing
- Hydros, Hydros-TA, Triamcinolone Acetonide
- Where
- 5 sites in Australia, Canada and 1 more
- Volunteers
- 510 people
- Sponsor
- Carbylan Therapeutics, Inc.